Novartis India to acquire Pfizer’s Minipress trademarks for ₹1,250 crore

The deal includes trademarks registered in India and related intellectual property rights, with Minipress XL generating ₹228.6 crore revenue in the year ended July 2026.

Mumbai: Novartis India’s board has approved the acquisition of the Minipress and Minipres trademarks registered in India from Pfizer Inc and Pfizer Products Inc for Rs 1,250 crore.The deal also covers certain intellectual property rights linked to the brands, the company said in an exchange filing.Following the approval, Novartis India signed an asset purchase agreement and trademark assignment deeds with the two Pfizer entities. The signing and completion of the transaction took place simultaneously.Minipress XL generates Rs 228.6 crore revenueMinipress XL recorded revenue of Rs 228.6 crore and delivered a compound annual growth rate of 6.3 percent over the past four years, according to IQVIA MAT July 2026 data cited by Novartis India.The broader category expanded at a faster CAGR of 9 percent during the same period.Minipress XL contains prazosin and is primarily prescribed for treating hypertension, or high blood pressure. It is also used to manage urinary symptoms associated with benign prostatic hyperplasia.Novartis India said the acquisition is not a related-party transaction. Pfizer Inc and Pfizer Products Inc are also unrelated to its promoter, promoter group or group companies.Pfizer discontinues sales in IndiaSeparately, Pfizer said it would discontinue the marketing, distribution and sale of Minipress XL in India from September 7, 2026.The move follows Pfizer Inc’s decision to stop manufacturing the medicine. Sensex, Nifty Start In The Red As IPO Frenzy And Middle East Tensions Rattle MarketsPfizer Ltd will receive a lump-sum payment of USD 13.9 million, equivalent to approximately Rs 131.38 crore, from its US-based parent in connection with the discontinuation.Pfizer shares were trading 0.8 percent lower at Rs 4,572.70 on the NSE at 11:45 am.Dr Reddy’s agreement endsThe acquisition comes after Dr Reddy’s Laboratories terminated its distribution and promotion agreement with Novartis India for select domestic brands following a change in Novartis India’s controlling shareholding. NSE IPO Grey Market Premium Hits ₹285 Ahead Of Expected September ListingDr Reddy’s will continue commercialising the covered brands until September 30, 2026.Novartis India shares were trading 2.9 percent higher at Rs 1,683.35 on the BSE at 11:45 am. The stock has gained around 68 percent in 2026.